Clinical information (n = 25)

Duration of ICI therapy, days, median (IQR)54 (1–525)
Number of ICI infusions at time of onset, median (IQR)4 (1–21)
Time from ICI initiation to onset, months, median (IQR)6 (0.1–31)
Duration of symptoms, days, median (IQR)5 (3–12)
Peak biochemistry values, median (IQR)
 White blood cell count, cells/L7.8 (0.7–33.0)
 Total bilirubin, mg/dL1.4 (0.4–36.1)
 Direct bilirubin, mg/dL0.9 (0.2–33.4)
 Alkaline phosphatase, IU/L167 (34–1281)
 ALT, IU/L55 (12–364)
 AST, IU/L47 (16–434)
Cholecystitis clinical presentation, n (%)
 Abdominal pain18 (72)
 Nausea and vomiting11 (44)
 Diarrhea3 (12)
 Fever5 (20)
Positive infectious workup at time of onset, n (%)2 (8)
Histopathologic examination performed, n (%)4 (16)

ICI immune checkpoint inhibitor, IQR interquartile range, ALT alanine aminotransferase, AST aspartate aminotransferase